Vertaling van "year-end 2009 share " (Nederlands → Frans) :

Based on the year-end 2009 share price of CHF 56.50, the dividend yield is 3.7%.
Sur la base du cours de clôture de CHF 56,50 de l’action à fin 2009, le rendement du dividende se situe à 3,7%.

Based on the year-end 2008 share price of CHF 52.70, the dividend yield rises to 3.8% from 2.6% in 2007.
Sur la base du cours de l’action de CHF 52,70 à la fin de l’exercice 2008, le rendement sur dividende de l’action Novartis progresse à 3,8%, contre 2,6% en 2007.

Overall liquidity rose to USD 17.4 billion at December 31, 2009, more than double the year-end 2008 level of USD 6.1 billion, underpinned by increasing cash flow from operations and proceeds from the bond issues.
Le total des liquidités a progressé à USD 17,4 milliards au 31 décembre 2009, atteignant ainsi plus du double du niveau d’USD 6,1 milliards à fin 2008, soutenu par une augmentation des flux de trésorerie provenant des activités et par le produit des emprunts obligataires.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Basic earnings per share Basic earnings per share (EPS) were USD 2.69 in the first nine months of 2009, down from USD 2.93 in the year-ago period.
Résultat de base par action Le résultat de base par action (RPA) a reculé à USD 2,69 au cours de neuf premiers mois de 2009, comparé à USD 2,93 pour la période comparable de l'exercice précédent.

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).

Earnings per share Basic earnings per share (EPS) in the fourth quarter were up 53% to USD 1.01 from USD 0.66 in the 2008 quarter, while full-year basic EPS rose 3% to USD 3.70 compared to USD 3.59 in 2008, at a slightly slower pace than net income in 2009 due to higher net income attributable to minority interests.
Résultat par action Au quatrième trimestre 2009, le résultat de base par action (BPA) a gagné 53% à USD 1,01 contre USD 0,66 au même trimestre de 2008, alors que sur l’exercice entier, le BPA de base s’est relevé de 3% à USD 3,70 en comparaison d’USD 3,59 en 2008. Ce léger ralentissement de la progression par rapport au résultat net est dû à un accroissement du résultat net attribuable aux intérêts minoritaires.

Q3 2010 Q3 2009 9M 2010 9M 2009 USD m USD m USD m USD m Share of estimated Roche reported net income 173 176 480 461 Catch-up for actual Roche previous year net income -40 Genentech restructuring impact -97 -43 -97 Amortization of intangible assets -35 -36 -101 -98 Net income effect from Roche 138 43 336 226 Share of Alcon, Inc reported US GAAP net income 118 139 400 368 Catch-up for actual up to August 25, 2010 Alcon, Inc net income -15 -13 5
Impact de la restructuration de Genentech -97 -43 -97 Amortissement d’immobilisations incorporelles -35 -36 -101 -98 Effet de l’investissement dans Roche sur le résultat net 138 43 336 226 Part du résultat net d’Alcon présenté sl. US GAAP 118 139 400 368 Ajustement au résultat net effectif d’Alcon jusqu’au 25 août 2010 -15 -13 5